BACKGROUND AND OBJECTIVES: Abnormal activation of several signal transduction pathways such as phosphoinositide 3-kinase (PI3K) and MAP kinases has been reported in acute myeloid leukemia (AML). To test new targeted therapeutics, it is critical to develop sensitive analytical tools to detect abnormal activation of these pathways and to monitor their inhibition in response to treatment. DESIGN AND METHODS: We analyzed Akt and ERK phosphorylation in 32 samples from patients using western blot and a two-color flow cytometry protocol using CD34. To circumvent the CD34 negative AML found in our series, we developed a two-color protocol using CD45 to isolate the blast cell population. Finally, a four-color protocol was used to detect phosphorylation in an enriched population of AML stem cells. RESULTS: We compared western blot analysis and flow cytometry for the detection of PI3K/Akt and ERK activation and found a 100% correlation between the two techniques in a series of 32 AML samples. Using a flow cytometry protocol, we were able to analyze all the patients' samples, even those with low blast infiltration or CD34 negative blast cells. We were also able to detect the phosphorylated proteins in the most immature blast cell population with the CD34+ CD38-/low CD123+ phenotype. Interpretations and CONCLUSION: Our study shows that flow cytometry is a reliable method for detecting Akt and ERK phosphorylation in all patients' samples. Activation can also be detected in the most immature blast cells, which represent exquisite target cells for new therapeutics.
BACKGROUND AND OBJECTIVES: Abnormal activation of several signal transduction pathways such as phosphoinositide 3-kinase (PI3K) and MAP kinases has been reported in acute myeloid leukemia (AML). To test new targeted therapeutics, it is critical to develop sensitive analytical tools to detect abnormal activation of these pathways and to monitor their inhibition in response to treatment. DESIGN AND METHODS: We analyzed Akt and ERK phosphorylation in 32 samples from patients using western blot and a two-color flow cytometry protocol using CD34. To circumvent the CD34 negative AML found in our series, we developed a two-color protocol using CD45 to isolate the blast cell population. Finally, a four-color protocol was used to detect phosphorylation in an enriched population of AML stem cells. RESULTS: We compared western blot analysis and flow cytometry for the detection of PI3K/Akt and ERK activation and found a 100% correlation between the two techniques in a series of 32 AML samples. Using a flow cytometry protocol, we were able to analyze all the patients' samples, even those with low blast infiltration or CD34 negative blast cells. We were also able to detect the phosphorylated proteins in the most immature blast cell population with the CD34+ CD38-/low CD123+ phenotype. Interpretations and CONCLUSION: Our study shows that flow cytometry is a reliable method for detecting Akt and ERK phosphorylation in all patients' samples. Activation can also be detected in the most immature blast cells, which represent exquisite target cells for new therapeutics.
Authors: Elias Kassab; Manal Darwish; Zahra Timsah; Shihui Liu; Stephen H Leppla; Arthur E Frankel; Ralph J Abi-Habib Journal: Transl Oncol Date: 2013-02-01 Impact factor: 4.243
Authors: Volker Wacheck; Michael Lahn; Gemma Dickinson; Wolfgang Füreder; Renata Meyer; Susanne Herndlhofer; Thorsten Füreder; Georg Dorfner; Sada Pillay; Valérie André; Timothy P Burkholder; Jacqueline K Akunda; Leann Flye-Blakemore; Dirk Van Bockstaele; Richard F Schlenk; Wolfgang R Sperr; Peter Valent Journal: Cancer Manag Res Date: 2011-05-10 Impact factor: 3.989